Vaccitech plc Stock News

Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatiti

OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutic

OSLO, Norway--(BUSINESS WIRE)--Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the disc

OSLO, Norway--(BUSINESS WIRE)--Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vacci

Vaccitech plc (NASDAQ:VACC) Analysts at Jefferies Financial Group decreased their FY2021 EPS estimates for shares of Vaccitech in a research note issued to investors on Monday, November 15th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of ($1.13) for the year, down from their prior forecast []

Vaccitech plc (NASDAQ:VACC) Analysts at William Blair lifted their FY2021 earnings estimates for shares of Vaccitech in a research report issued on Monday, November 15th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($1.14) per share for the year, up from their prior forecast of ($1.67). William Blair []

Squarepoint Ops LLC bought a new position in Vaccitech plc (NASDAQ:VACC) in the second quarter, HoldingsChannel reports. The fund bought 25,000 shares of the companys stock, valued at approximately $420,000. Other large investors have also modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in Vaccitech in the 2nd quarter []

Vaccitech (NASDAQ:VACC)s stock had its buy rating reiterated by research analysts at HC Wainwright in a report released on Monday, TipRanks reports. They currently have a $24.00 price target on the stock. HC Wainwrights price target points to a potential upside of 88.24% from the companys previous close. A number of other equities analysts have []

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-

Vaccitech is the company behind the COVID-19 vaccine that was developed in partnership with Oxford University for AstraZeneca. The company has several other vaccine candidates for Hepatitis B, HPV, he

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics a

Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared fi